In the proliferation assays, we examined effect of KLHL33 silencing at different doses and found that only resistance to Sunitnib was observed whilst proliferation was not altered in ccRCC cell treated with Sorafenib (Additional file 1: Figure S1). Here, KLHL33 is linked to nonpapillary renal cell carcinoma.